tiprankstipranks
Nanomix (NNMX)
OTHER OTC:NNMX
US Market
Holding NNMX?
Track your performance easily

Nanomix (NNMX) Stock Price & Analysis

20 Followers

NNMX Stock Chart & Stats


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

NNMX FAQ

What was Nanomix’s price range in the past 12 months?
Currently, no data Available
What is Nanomix’s market cap?
Currently, no data Available
When is Nanomix’s upcoming earnings report date?
Nanomix’s upcoming earnings report date is May 17, 2022 which is 953 days ago.
    How were Nanomix’s earnings last quarter?
    Nanomix released its earnings results on Apr 16, 2019. The company reported -$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.009.
      Is Nanomix overvalued?
      According to Wall Street analysts Nanomix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Nanomix pay dividends?
        Nanomix does not currently pay dividends.
        What is Nanomix’s EPS estimate?
        Nanomix’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Nanomix have?
        Nanomix has 48,996,760 shares outstanding.
          What happened to Nanomix’s price movement after its last earnings report?
          Nanomix reported an EPS of -$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.65%.
            Which hedge fund is a major shareholder of Nanomix?
            Currently, no hedge funds are holding shares in NNMX
            ---

            Company Description

            Nanomix

            Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            T2 Biosystems
            VolitionRX
            QuidelOrtho
            Accelerate Diagnostics
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis